Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia. - Wikidata - awgldk - TriplyDB

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia.

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia.

http://www.wikidata.org/entity/Q34640779

about

Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance.Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia Selective JAK inhibitors in development for rheumatoid arthritis.Novel targeted therapy for acute myeloid leukemia with a dual FLT3 and JAK2 inhibitor The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML.Gene mutations and molecularly targeted therapies in acute myeloid leukemia.Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia.Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application.The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer.Profile of pacritinib and its potential in the treatment of hematologic disorders.A comprehensive review of pacritinib in myelofibrosis.Cytokine Signaling in Tumor Progression.Role of interleukin-6 in cancer progression and therapeutic resistance.The genetics of gastroesophageal adenocarcinoma and the use of circulating cell free DNA for disease detection and monitoring.Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor.Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia.Ruxolitinib significantly enhances in vitro apoptosis in Hodgkin lymphoma and primary mediastinal B-cell lymphoma and survival in a lymphoma xenograft murine model.

P2860

Q28538435-A1AB68D2-2AA1-4F85-A201-AA9C940F03A7 Q30251920-A911FBC8-8CF2-4310-8CFD-9E86A73D6D04 Q33437478-E14AEB2B-6FFB-482B-B4A8-5CA060D430F2 Q33943277-195903DB-B9CA-4E82-AF85-F58C2E0355D7 Q34419615-909DBCBC-4DA5-4E94-B710-A158061806ED Q34634995-568C451A-D82B-4337-A79E-FFE3572FA949 Q34640790-9CEA1E0A-C0D2-4CC1-A850-891F62908110 Q34647741-17D256AB-748B-4A60-BE28-3159FA4F0D15 Q34817365-9534082B-A02B-4EA6-A833-87B3747CB98A Q35835233-B9D8E66F-4AFA-4B65-B176-D3887091D74A Q38164139-2CF945D9-546A-4530-A01A-1751D9C3C185 Q38203779-0EF02086-9E21-47CA-A7CA-70DCC073F67F Q38244524-2C064A4B-7044-4ACB-B588-A5FE4D67E8FF Q38586421-F056784D-C027-4EED-B2B3-EC68C0FCD68B Q38598868-53581D6E-4040-4224-93DB-1C0432D79630 Q38853625-F4716C5C-F214-45A8-951A-D4624A938A28 Q39183864-29867785-B6FC-4967-9B1A-807715AFF444 Q41448224-9207C70E-29A3-4344-93EC-36053BB993D7 Q47100599-6A8CF925-AA5A-4572-8A46-500364427DA4 Q52668197-667AFD45-DA00-489E-8D4F-FE2A1C15762E

P2860

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia.

http://www.wikidata.org/entity/Q34640779

description

2011 nî lūn-bûn

@nan

2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia.

@ast

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia.

@en

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia.

@nl

type

label

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia.

@ast

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia.

@en

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia.

@nl

prefLabel

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia.

@ast

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia.

@en

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia.

@nl

P1433

Q34640779-7FE4E333-7D56-4A4D-AA79-20C44177EC61

P1476

Q34640779-AFE8D0E4-602A-48FD-8927-76E2FFF75E84

P2093

Q34640779-095E2C66-B324-4EDB-A8F9-27D83EC39F23

Q34640779-2679C01A-5245-4B23-87F3-3EE3DB0FBD17

Q34640779-2D31FF52-D2CF-44FE-BDBF-80B079DAC39A

Q34640779-31CCBD85-C793-48A3-AFDF-B3B13426CC38

Q34640779-5C159AF4-98D2-4CB3-90EA-82624F2F2172

Q34640779-5F14B420-A079-44F9-91C6-DB8D7979E995

Q34640779-73D4E40C-5FB6-4250-A0AF-01533AA05CF6

Q34640779-79471477-D535-4B82-831E-AF93E6FE8D43

Q34640779-7EC872FB-8B0F-4ED0-A8BA-76335870DB79

Q34640779-C7569411-0E79-495D-8AE7-B95B1FA98ACE

P2860

Q34640779-03C2721A-CAC0-431A-9E7F-C1BBAD05A38E

Q34640779-0E94730E-211E-4172-9694-AF15B4B7B77B

Q34640779-157E4160-CB92-4774-8225-5CB1EDF7F4D8

Q34640779-21330844-7FAD-4890-9975-16AC3016C8E6

Q34640779-272F472B-1897-4396-9EAC-CD8EB402CA1E

Q34640779-27FD7348-DF8C-43CA-AB38-3B32DAB791E0

Q34640779-2D0C8FC2-5A65-4114-A948-2A6E454C628D

Q34640779-2EEF23D7-9E5E-47CA-BB02-98187D9A72FD

Q34640779-4365A2B2-0E0C-44A7-B409-A3DE8937E1AC

Q34640779-4B6963DC-A86F-41F1-837A-8B616C741C68

P2888

Q34640779-B228EB76-1D03-4959-8F32-6052580F201D

P304

Q34640779-52DBD9BC-5416-40C0-8BB3-472C1F355C59

P31

Q34640779-68F82867-50E5-43ED-8427-B29154C6EFBC

P356

Q34640779-3113BABA-B222-4F2E-93D3-F26178855152

P433

Q34640779-1D736046-FE1E-443C-B79B-38A25AEFE9A7

P478

Q34640779-0E856551-3D91-4AB8-8F9D-A65673160B7E

P577

Q34640779-9DBB6C4B-3DB8-4DE2-B863-94DB7D79E711

P5875

Q34640779-7F8FA6D8-D3C9-488F-85F8-4975228AAB5B

P6179

Q34640779-929B6924-885B-4C3E-BAAC-84842B200939

P698

Q34640779-296E40D7-5B00-461D-B4BF-D50AB29E8C09

P921

Q34640779-E464D95B-3782-46F5-B33E-6486FAF56FBD

P932

Q34640779-A2A33927-C67E-49E4-AC8D-A97C139ACFD0

P356

P1433

Blood Cancer Journal

P1476

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia.

@en

P2093

A Cheong

http://www.w3.org/2001/XMLSchema#string

B Kheng

http://www.w3.org/2001/XMLSchema#string

B Madan

http://www.w3.org/2001/XMLSchema#string

C Amalini

http://www.w3.org/2001/XMLSchema#string

J M Wood

http://www.w3.org/2001/XMLSchema#string

J Zhou

http://www.w3.org/2001/XMLSchema#string

K C Goh

http://www.w3.org/2001/XMLSchema#string

L C Ong

http://www.w3.org/2001/XMLSchema#string

S Hart

http://www.w3.org/2001/XMLSchema#string

V Novotny-Diermayr

http://www.w3.org/2001/XMLSchema#string

P2860

CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells

Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells

FLT3 as a therapeutic target in AML: still challenging after all these years

Drug combination studies and their synergy quantification using the Chou-Talalay method

Malignant epithelioid angiomyolipoma ('sarcoma ex angiomyolipoma') of the kidney: a case report and review of the literature.

Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhi

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies.

P2888

P304

e44

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BCJ.2011.43

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230565358

http://www.w3.org/2001/XMLSchema#string

P6179

1006006579

http://www.w3.org/2001/XMLSchema#string

P698

22829080

http://www.w3.org/2001/XMLSchema#string

P921

P932

3256753

http://www.w3.org/2001/XMLSchema#string